AFST Chairman’s contract report 1 April 2012 to 31 March 2013

The Antifungal Susceptibility Testing Subcommittee (AFST) continues to work on breakpoints and methods for antifungal agents. The general committee met once, on 1st of April during ECCMID in London. The AFST steering committee met separately on 1st through 3rd of October 2012 in Copenhagen Denmark.

The following breakpoints were established and made available at the AFST section at EUCAST.org

1. Itraconazole and Aspergillus V. 1.1 (6th June, 2012)
2. Voriconazole and Aspergillus V. 1.0 (20th May 2012)
3. Micafungin and Candida V. 1.0 (22nd February 2013)

The following breakpoints were revised and are made available at the AFST section at EUCAST.org

1. Fluconazole and Candida V. 2.0 (23rd February 2013)
2. Anidulafungin and Candida V. 2.0 (25th February 2013)

The following technical notes have been prepared and published in the Clin Microbiol Infect journal:


The following technical note have been prepared and accepted for publication in the Clin Microbiol Infect journal:

1. EUCAST Technical Note on Aspergillus and voriconazole.

The following oral presentations have been given by the AFST SC members specifically addressing and presenting the EUCAST AFST work:

4. “Susceptibility testing of fungi according to the new EUCAST recommendations”. Maiken Cavling Arendrup. ÖGMM-Workshop. Wien, Austria. (23 Nov. 2012.)

Ongoing work
Currently the AFST are collecting data for the establishment of isavuconazole ECOFFs for Candida and Aspergillus in order to assure such can be ready as soon as this new compound is launched (expected 2014). Also a technical note on micafungin and Candida will be prepared for the Clin Microbiol Inf journal. A poster has been accepted for presentation at ECCMID summarising the micafungin ECOFFs. Development of breakpoints for antifungal compounds for which none have yet been selected.